In a retrospective cohort study of a registry of Danish patients aged 40 years and older who underwent total joint replacement in 1998–2007, starting therapy with oral bisphosphonates after arthroplasty seemed to improve implant survival. Among bisphosphonate users, 27 out of 1,558 (1.73%) underwent revision surgery during the study follow-up period (median 2.61 years), compared with 399 of 8,966 (4.45%) matched non-users.